Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,390.00    108.00 (4.73%)
Bid:
2,380.00
Ask:
2,384.00
Spread: 4.00 (0.168%)
Market Cap: £7.67b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

24 Jun 2025 07:00

RNS Number : 0410O
Bunzl PLC
24 June 2025
 

24 June 2025

 BUNZL PRE-CLOSE STATEMENT

Trading in-line with expectations; acquisition agreed in Brazil

 

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the six months ending 30 June 2025.

Group revenue over the period is expected to be approximately 4% higher than the prior year, at constant exchange rates, and up to 1% higher at actual exchange rates. Group revenue growth at constant exchange rates is expected to be driven by acquisitions, net of disposals, and with broadly flat underlying revenue over the period1. We expect Group operating margin over the period to be in-line with previously published guidance at around 7.0%, with the expected Group adjusted operating profit decline also in-line with expectations.

2025 guidance

As per our statement on 16th April, the Group expects moderate revenue growth in 2025, at constant exchange rates, driven by announced acquisitions and broadly flat underlying revenue. Group operating margin for the year is expected to be moderately below 8.0%, compared to 8.3% in 2024. The Group's second half operating margin is seasonally higher and expected to benefit from actions taken.

Capital allocation update

In May, Bunzl signed an agreement to acquire Solupack, a Brazilian distributor of own brand packaging solutions to the food industry. In 2024 the business generated revenue of BRL 106 million (c.£ 15 million), and alongside our existing business will enhance our offering to customers. The acquisition is subject to competition authority clearance.

At the end of June we expect our leverage to be around 2.0 times, consistent with our aim to be towards the lower end of our target range of 2.0 to 2.5 times adjusted net debt to EBITDA by the end of 2025, after potential acquisition spend.

 

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

"Alongside a macroeconomic backdrop that remains uncertain, the Group is trading in-line with our expectations. Actions are underway to improve performance in the Group, particularly in our largest business in North America and in Continental Europe, and we anticipate improvement in the second half of the year.

I am also pleased to welcome Solupack to the Bunzl family today, our third acquisition of the year, with our pipeline remaining active. The Group's compounding growth strategy and resilient business model underpin Bunzl's long-term track record of delivery and the Group continues to be well placed to navigate periods of macroeconomic uncertainty given our focus on essential products, the depth of our customer and supplier relationships and our sector and geographic diversification."

Enquiries:

 Bunzl plc

 Frank van Zanten, Chief Executive Officer

 Richard Howes, Chief Financial Officer

 Sunita Entwisle, Head of Investor Relations and Communications

 Tel: +44 (0)20 7725 5000

Teneo

Martin Robinson

Giles Kernick

Tel: +44 (0)20 7353 4200

1. The impact of fewer trading days is also expected to have a slight impact on revenue.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUGDLIXDDGUX
Date   Source Headline
18th Apr 20248:00 amRNSAdditional Listing
11th Apr 20248:00 amRNSAdditional Listing
3rd Apr 20245:28 pmRNSDirector/PDMR Shareholding
3rd Apr 20249:09 amRNSDirector/PDMR Shareholding
2nd Apr 20241:50 pmRNSTotal Voting Rights
21st Mar 20248:00 amRNSAdditional Listing
15th Mar 20243:28 pmRNSAnnual Financial Report
7th Mar 20248:00 amRNSAdditional Listing
5th Mar 20245:05 pmRNSDirector/PDMR Shareholding
4th Mar 20243:03 pmRNSDirector/PDMR Shareholding
1st Mar 202411:35 amRNSTotal Voting Rights
28th Feb 20243:17 pmRNSDirector/PDMR Shareholding
27th Feb 20245:26 pmRNSDirector/PDMR Shareholding
26th Feb 202410:30 amRNSDividend Declaration
26th Feb 20247:00 amRNSFinal Results
26th Feb 20247:00 amRNSAcquisition
5th Feb 20242:20 pmRNSDirector/PDMR Shareholding
1st Feb 20245:08 pmRNSTotal Voting Rights
12th Jan 20244:54 pmRNSDirector/PDMR Shareholding
11th Jan 20243:50 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:57 amRNSTotal Voting Rights
15th Dec 20235:10 pmRNSHolding(s) in Company
14th Dec 20237:00 amRNSTrading Statement
8th Dec 20235:32 pmRNSDirector/PDMR Shareholding
1st Dec 202311:32 amRNSTotal Voting Rights
20th Nov 20236:30 pmRNSPublication of Admission Particulars
3rd Nov 20239:30 amRNSDirector Declaration
2nd Nov 20232:29 pmRNSDirector/PDMR Shareholding
1st Nov 202311:24 amRNSTotal Voting Rights
1st Nov 20239:00 amRNSBlock listing Interim Review
24th Oct 20237:00 amRNSTrading Statement
6th Oct 20235:08 pmRNSDirector/PDMR Shareholding
4th Oct 20231:40 pmRNSDirector/PDMR Shareholding
2nd Oct 20231:34 pmRNSTotal Voting Rights
2nd Oct 20231:33 pmRNSDirector/PDMR Shareholding
26th Sep 20232:10 pmRNSDirector/PDMR Shareholding
1st Sep 20232:30 pmRNSTotal Voting Rights
31st Aug 202310:30 amRNSDirector/PDMR Shareholding
29th Aug 202310:00 amRNSDividend Declaration
29th Aug 20237:00 amRNSHalf-year Report
29th Aug 20237:00 amRNSAcquisition
15th Aug 20237:00 amRNSAcquisition
2nd Aug 20233:45 pmRNSDirector/PDMR Shareholding
1st Aug 202311:17 amRNSTotal Voting Rights
13th Jul 20234:20 pmRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSOutcome of audit tender process
11th Jul 20234:50 pmRNSDirector/PDMR Shareholding
6th Jul 202310:44 amRNSDirector/PDMR Shareholding
3rd Jul 20234:45 pmRNSTotal Voting Rights
29th Jun 20233:26 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.